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Abstract 
Serpins are a broadly distributed family of protease inhibitors that use a conformational change to
inhibit target enzymes. They are central in controlling many important proteolytic cascades,
including the mammalian coagulation pathways. Serpins are conformationally labile and many of
the disease-linked mutations of serpins result in misfolding or in pathogenic, inactive polymers. 
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Serpins (serine protease inhibitors or classified inhibitor
family I4) are the largest and most broadly distributed
superfamily of protease inhibitors [1,2]. Serpin-like genes
have been identified in animals, poxviruses, plants, bacteria
and archaea, and over 1,500 members of this family have
been identified to date. Analysis of the available genomic
data reveals that all multicellular eukaryotes have serpins:
humans, Drosophila, Arabidopsis thaliana and Caenorhab-
ditis elegans have 36, 13, 29, and about 9 serpin-like genes,
respectively [1,3]. In contrast, serpins in prokaryotes are
sporadically distributed and most serpin-containing
prokaryotes have only a single serpin gene [4]. The majority
of serpins inhibit serine proteases, but serpins that inhibit
caspases [5] and papain-like cysteine proteases [6,7] have
also been identified. Rarely, serpins perform a non-
inhibitory function; for example, several human serpins
function as hormone transporters [8] and certain serpins
function as molecular chaperones [9] or tumor suppressors
[10]. A phylogenetic study of the superfamily divided the
eukaryotic serpins into 16 ‘clades’ (termed A-P) [1]. The pro-
teins are named SERPINXy, where X is the clade and y is the
number within that clade; many serpins also have alterna-
tive names from before this classification was proposed. 
Serpins are relatively large molecules (about 330-500 amino
acids) in comparison with protease inhibitors such as basic
pancreatic trypsin inhibitor (BPTI, which is about 60 amino
acids) [11]. Over 70 serpin structures have been determined,
and these data, along with a large amount of biochemical
and biophysical information, reveal that inhibitory serpins
are ‘suicide’ or ‘single use’ inhibitors that use a unique and
extensive conformational change to inhibit proteases [12].
This conformational mobility renders serpins heat-labile and
vulnerable to mutations that promote misfolding, sponta-
neous conformational change, formation of inactive serpin
polymers and serpin deficiency [13]. In humans, several con-
formational diseases or ‘serpinopathies’ linked to serpin
polymerization have been identified, including emphysema
(SERPINA1 (antitrypsin) deficiency) [14], thrombosis
(SERPINC1 (antithrombin) deficiency) [15] and angio-
edema (SERPING1 (C1 esterase inhibitor) deficiency) [16].
Accumulation of serpin polymers in the endoplasmic reticu-
lum of serpin-secreting cells can also result in disease, most
notably cirrhosis (SERPINA1 polymerization) [14] and
familial dementia (SERPINI1 (neuroserpin) polymerization)
[17]. Other serpin-related diseases are caused by null muta-
tions or (rarely) point mutations that alter inhibitoryspecificity or inhibitory function [18]. Here, we summarize
the evolution, structure and mechanism of serpin function
and dysfunction. 
Broad organization of the serpin superfamily
Serpins appear to be ubiquitous in multicellular higher
eukaryotes and in the poxviridae pathogens of mammals. In
humans, the two largest clades of the 36 serpins that have
been identified are the extracellular ‘clade A’ molecules (thir-
teen members found on chromosomes 1, 14 and X) and the
intracellular ‘clade B’ serpins (thirteen members on chromo-
somes 18 and 6) [3].
Recent bioinformatic and structural studies have also identi-
fied inhibitory serpins in the genomes of certain primitive
unicellular eukaryotes (such as Entamoeba histolytica [19])
as well as prokaryotes [4,20]. No fungal serpin has been
identified to date, and the majority of prokaryotes do not
contain clearly identifiable serpin-like genes. Phylogenetic
analyses have found no evidence for horizontal transfer
[1,21], and it is instead suggested that serpins are ancient
proteins and that most prokaryotes have lost the require-
ment for serpin-like activity [4]. 
Functional diversity of serpins
Inhibitory serpins have been shown to function in processes
as diverse as DNA binding and chromatin condensation in
chicken erythrocytes [22,23], dorsal-ventral axis formation
and immunoregulation in Drosophila and other insects
[24,25], embryo development in nematodes [26], and
control of apoptosis [5]. 
In humans, the majority (27 out of 36) of serpins are
inhibitory (Table 1). Clade A serpins include inflammatory
response molecules such as SERPINA1 (antitrypsin) and
SERPINA3 (antichymotrypsin) as well as the non-inhibitory
hormone-transport molecules SERPINA6 (corticosteroid-
binding globulin) and SERPINA7 (thyroxine-binding globu-
lin). Clade B includes inhibitory molecules that function to
prevent inappropriate activity of cytotoxic apoptotic pro-
teases (SERPINB6, also called PI6, and SERPINB9, also
called PI9) and inhibit papain-like enzymes (SERPINB3,
squamous cell carcinoma antigen-1) as well as the non-
inhibitory molecule SERPINB5 (maspin). SERPINB5 does
not undergo the characteristic serpin-like conformational
change and functions to prevent metastasis in breast cancer
and other cancers through an incompletely characterized
mechanism [10,27]. The roles of several other well charac-
terized human serpins are also summarized in Table 1. 
Numerous important branches of the serpin superfamily
remain to be functionally characterized. For example,
although plants have a large number of serpin genes, the
function of plant serpins remains obscure. Studies in vitro
clearly show that plant serpins can function as protease
inhibitors [28], but plants lack close relatives of chy-
motrypsin-like proteases, which would be the obvious
targets for these serpins. Thus, it has been suggested that
plant serpins may be involved in inhibiting proteases in plant
pathogens; for example, they may be targeting digestive pro-
teases in insects [29]. One study convincingly demonstrated a
close inverse correlation between the upregulation of Cucur-
bita maxima (squash) phloem serpin-1 (CmPS) and aphid
survival [30]. Feeding experiments in vitro showed, however,
that purified CmPS did not affect insect survival [30].
Together, these data suggest that rather than directly inter-
acting with the pathogen, plant serpins, like their insect coun-
terparts, may have a role in the complex pathways involved
in upregulating the host immune response. 
Similarly, the role of serpins in prokaryotes remains to be
understood; again, these molecules are capable of inhibitory
activity in vitro [20], but their targets in vivo and their func-
tion remain to be characterized. Interestingly, several
inhibitory prokaryote serpins are found in extremophiles
that live at elevated temperatures (for example, Pyrobacu-
lum aerophilum, which lives at 100°C); these serpins use
novel strategies to function as inhibitors at elevated temper-
atures while resisting inappropriate conformational change
[4,20,31]. 
Structural biology of the serpins and the
mechanism of protease inhibition 
Serpins are made up of three  sheets (A, B and C) and 8-9 
helices (termed hA-hI). Figure 1a shows the native structure
of the archetypal serpin SERPINA1 [32]. The region respon-
sible for interaction with target proteases, the reactive center
loop (RCL), forms an extended, exposed conformation above
the body of the serpin scaffold. The remarkable conforma-
tional change characteristic of inhibitory serpins is depicted
in Figure 1d; the structure of SERPINA1 with its RCL cleaved
[33] shows that, following proteolysis, the amino-terminal
portion of the RCL inserts into the center of -sheet A to
form an additional (fourth) strand (s4A). This conforma-
tional transition is termed the ‘stressed (S) to relaxed (R)
transition’, as the cleavage of native inhibitory serpins
results in a dramatic increase in thermal stability. Native
serpins are therefore trapped in an intermediate, metastable
state, rather than their most stable conformation, and thus
represent a rare exception to Anfinsen’s conjecture, which
predicts that a protein sequence will fold to a single structure
that represents the lowest free-energy state [34]. 
Serpins use the S-to-R transition to inhibit target proteases.
Figure 1b shows the structure of an initial docking complex
between a serpin and a protease (SERPINA1 and trypsin
[35,36]) and Figure 1c shows the final serpin-enzyme
complex [12]. These structural studies [12,35,36], combined
with extensive biochemical data, revealed that RCL cleavage
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Table 1 
Function and dysfunction of human serpins
Serpin Alternative name(s) Protease target or function Involvement in disease
SERPINA1 Antitrypsin Extracellular; inhibition of neutrophil elastase Deficiency results in emphysema: 
polymerization and retention in the ER results
in cirrhosis [14,64,65]
SERPINA2 Antitrypsin-related protein Not characterized, probable pseudogene
SERPINA3 Antichymotrypsin Extracellular; inhibition of cathepsin G Deficiency results in emphysema (see [61] for 
a review)
SERPINA4 Kallistatin (PI4) Extracellular, inhibition of kallikrein [68]
SERPINA5 Protein C inhibitor (PAI-3) Extracellular; inhibition of active protein C  Angioedema
(see [69] for a review)
SERPINA6 Corticosteroid-binding globulin Extracellular; non-inhibitory; cortisol binding Deficiency linked to chronic fatigue [83,84]
SERPINA7 Thyroxine-binding globulin Extracellular; non-inhibitory, thyroxine binding Deficiency results in hypothyroidism [85]
SERPINA8 Angiotensinogen Extracellular; non-inhibitory; amino-terminal cleavage  Certain variants linked to essential 
by the protease renin results in release of the  hypertension [86]
decapeptide angiotensin I
SERPINA9 Centerin Extracellular; maintenance of naive B cells [70]
SERPINA10  Protein Z-dependent proteinase  Extracellular; inhibition of activated factor Z and XI Deficiency linked to venous thromboembolic 
inhibitor disease [87]
SERPINA11 XP_170754.3 Not characterized
SERPINA12 Vaspin Extracellular; insulin-sensitizing adipocytokine [71]
SERPINA13 XM_370772 Not characterized
SERPINB1  Monocyte neutrophil elastase  Intracellular; inhibition of neutrophil elastase [72]
inhibitor
SERPINB2 Plasminogen activator  Intracellular; inhibition of uPA (see [73] for a review)
inhibitor-2 (PAI2)
SERPINB3  Squamous cell carcinoma  Intracellular; cross-class inhibition of cathepsins L 
antigen-1 and V [6]
SERPINB4 Squamous cell carcinoma  Intracellular; cross-class inhibition of cathepsin G 
antigen-2 and chymase [74]
SERPINB5  Maspin Intracellular; non-inhibitory; inhibition of metastasis  Downregulation and/or intracellular location 
through uncharacterized mechanism linked to tumor progression and overall 
prognosis [10]
SERPINB6  Proteinase inhibitor-6 (PI6) Intracellular, inhibition of cathepsin G [75]
SERPINB7 Megsin Intracellular; megakaryocyte maturation [76] IgA nephropathy
SERPINB8 Cytoplasmic antiproteinase 8 (PI8) Intracellular; inhibition of furin [77]
SERPINB9  Cytoplasmic antiproteinase 9 (PI9) Intracellular, inhibition of granzyme B [78]
SERPINB10 Bomapin (PI10) Intracellular; inhibition of thrombin and trypsin [79]
SERPINB11 Epipin Intracellular
SERPINB12 Yukopin Intracellular; inhibition of trypsin [80]
SERPINB13 Headpin (PI13) Intracellular; inhibition of cathepsins L and K
SERPINC1  Antithrombin Extracellular; thrombin and factor Xa inhibitor Deficiency results in thrombosis (see [88] for 
review)
SERPIND1  Heparin cofactor II Extracellular; thrombin inhibitor May contribute to thrombotic risk when 
combined with other deficiencies [89]
SERPINE1  Plasminogen activator inhibitor 1  Extracellular; inhibitor of thrombin, uPA, tPA  Abnormal bleeding [90]
(PAI1) and plasmin 
SERPINE2 Protease nexin I (PI7) Extracellular; inhibition of uPA and tPA
SERPINE3 Hs.512272 Not characterized
SERPINF1  Pigment epithelium derived factor Non-inhibitory; potent anti-angiogenic molecule [81]
SERPINF2  Alpha-2-antiplasmin Extracellular; plasmin inhibitor Unrestrained fibrinolytic activity, bleeding [91]
SERPING1  C1 inhibitor C1 esterase inhibitor Angioedema [92]
SERPINH1  47kDa heat-shock protein Non-inhibitory molecular Chaperone for collagens [9]
SERPINI1  Neuroserpin (PI12) Extracellular; inhibitor of tPA, uPA and plasmin Polymerization results in dementia [17]
SERPINI2 Myoepithelium-derived serine Extracellular; inhibition of cancer metastasis [82]
proteinase inhibitor (PI14)and subsequent insertion is crucial for effective protease
inhibition. In the final serpin-protease complex, the protease
remains covalently linked to the serpin, the enzyme being
trapped at the acyl-intermediate stage of the catalytic cycle.
Structural comparisons show that the protease in the final
complex is severely distorted in comparison with the native
conformation, and that much of the enzyme is disordered
[12]. In addition, a fluorescence study demonstrated that the
protease was partially unfolded in the final complex [37].
These conformational changes lead to distortion at the active
site, which prevents efficient hydrolysis of the acyl interme-
diate and the subsequent release of the protease. These data
are consistent with the observation that buried or cryptic
cleavage sites within trypsin become exposed following
complex formation with a serpin [38]. It is possible that
cleavage of such cryptic sites within the protease occurs in
vivo and thus results in permanent enzyme inactivation. The
absolute requirement for RCL cleavage, however, means that
serpins are irreversible ‘suicide’ inhibitors. 
A major advantage of the serpin fold over small protease
inhibitors such as BPTI is that the inhibitory activity of
serpins can be exquisitely controlled by specific cofactors.
For example, human SERPINC1 (antithrombin) is a rela-
tively poor inhibitor of the proteases thrombin and factor Xa
until it is activated by the cofactor heparin [39]. Structural
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Figure 1
The structure and mechanism of inhibitory serpins. (a) The structure of native SERPINA1 (Protein Data Bank (PDB) code 1QLP) [32]. The A sheet is in
red, the B sheet in green and the C sheet in yellow; helices (hA-hI) are in blue. The reactive center loop (RCL) is at the top of the molecule, in magenta.
The position of the breach and the shutter are labeled and the path of RCL insertion indicated (magenta dashed line). Both of these regions contain
several highly conserved residues, many of which are mutated in various serpinopathies. (b) The Michaelis or docking complex between SERPINA1 and
inactive trypsin (PDB code 1OPH) [36], with the protease (multicolors) docked onto the RCL (magenta). Upon docking with an active protease (b), two
possible pathways are apparent. (c) The final serpin enzyme complex (PDB code 1EZX [12]). The serpin has undergone the S to R transition, and the
protease hangs distorted at the base of the molecule. (d) The structure of cleaved SERPINA1 is shown (PDB code 7API) [93]) with the RCL (magenta)
forming the fourth strand of -sheet A. The result of serpin substrate-like behavior can be seen where the protease has escaped the conformational trap,
leaving active protease and inactive, cleaved serpin. Certain serpin mutations, particularly non-conservative substitutions within the hinge region of the
RCL, result in substrate-like, rather than inhibitory, behavior [94].
+
Protease
Serpin
+
Cleaved
serpin
Active protease
RCL
RCL (a) (b)
(d)
Breach
Shutter
Final (covalent) complex
RCL (c)
Docking 
(Michaelis) complex studies of SERPINC1 highlight the molecular basis for
heparin function. Figure 2a shows the structure of native
SERPINC1. Here, we use the convention of Schechter and
Berger, in which residues on the amino-terminal side of the
cleavage site (P1/P1) are termed P2, P3, and so on, and
those carboxy-terminal are termed P2, P3, and so on; cor-
responding subsites in the enzyme are termed S1, S2, and so
on [40]. The RCL is partially inserted into the top of the 
sheet; the residue (P1-Arg) responsible for docking into the
primary specificity pocket (S1) of the protease is relatively
inaccessible to docking with thrombin, as it is pointing
towards and forming interactions with the body of the serpin
[41,42]. Figure 2b illustrates the ternary complex between
SERPINC1, thrombin and heparin [43]. Upon interaction
with a specific heparin pentasaccharide sequence present in
high-affinity heparin, SERPINC1 undergoes a substantial
conformational rearrangement whereby the RCL is expelled
from  -sheet A and the P1 residue flips to an exposed
protease-accessible conformation [44-46]. In addition to
loop expulsion and P1 exposure, long-chain heparin can bind
both enzyme and inhibitor and thus provides an additional
acceleration of the inhibitory interaction. Several other
serpins, including SERPIND1 (heparin cofactor II), also use
cofactor binding and conformational change to achieve
exquisite inhibitory control [47]. 
Structural studies on prokaryote and viral serpins have
revealed several interesting variations of the serpin scaffold.
Viral proteins are often ‘stripped down’ to a minimal scaffold
in order to minimize the size of the viral genome. Consistent
with this requirement, the structure of the viral serpin crmA,
one of the smallest members of the serpin superfamily
[48,49], shows that it lacks helix hD. More recently, the
structure of the prokaryote serpin thermopin from Ther-
mobifida fusca revealed the absence of helix hH [20,31].
These studies also showed that thermopin contains a
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Figure 2
Modulation of serpin conformation by cofactors. (a) The structure of native SERPINC1 (PDB code 2ANT) [95]. The partial insertion of the RCL (two
residues) into the top of -sheet A is circled, and the position of the P1 residue is shown (magenta spheres). (b) The structure of the ternary complex
between SERPINC1, inactive thrombin (the Ser195Ala mutant) and a synthetic long-chain heparin construct (PDB code 1TB6) [43]. A specific high-affinity
pentasaccharide (green) on the heparin interacts with the heparin-binding site on SERPINC1 (on and around helix hD) and promotes expulsion of the
RCL (blue arrow) and rearrangement of the P1 residue (magenta spheres). 
P1
Serpin
Ternary complex
(a) (b)
Protease Heparin
++4 amino-acid insertion at the carboxyl terminus that forms
extensive interactions with conserved residues at the top of
-sheet A (called the ‘breach’; see later); biophysical data
suggest that this region is important for proper and efficient
folding of this unusual serpin. 
The major conformational change that occurs within both
the protease and the serpin as a result of serpin-enzyme
complex formation provides an elegant mechanism for cells
to specifically detect and clear inactivated serpin-protease
complexes. Several studies have shown that the low density
lipoprotein-related protein (LRP) specifically binds to and
promotes internalization of the final complexes SERPINC1-
thrombin, SERPIND1-thrombin and SERPINA1-trypsin. In
contrast, native or cleaved serpin alone are not internalized
[50]. Additionally, recent studies on SERPINI1 show that
both SERPINI1-tissue plasminogen activator complexes and
native SERPINI1 are internalized in an LRP-dependent
manner. However, while SERPINI1-tissue plasminogen acti-
vator complexes can bind directly to LRP, native SERPINI1
requires the presence of an (as yet unidentified) cofactor
[51]. The structural basis for interaction of LRP with serpin-
enzyme complexes and the subsequent intracellular signal-
ing response remain to be fully understood. It is clear,
however, that native serpins and serpin-enzyme complexes
can induce powerful responses such as cell migration in an
LRP-dependent manner [52]. 
Inactivation of serpins: latency, polymerization,
deficiency and disease
The metastability of serpins and their ability to undergo con-
trolled conformational change also renders these molecules
susceptible to spontaneous conformational rearrangements.
Most notably, the serpin SERPINE1 (plasminogen activator
inhibitor-1) uses spontaneous conformational change to
control inhibitory activity [53]. Structural and biochemical
studies show that, in the absence of the cofactor vitronectin,
native SERPINE1 (Figure 3a) rapidly converts to a latent
inactive state (Figure 3b). The transition to latency is accom-
panied by insertion of the RCL into -sheet A, where it
cannot interact with the target protease. Interestingly, the
structure of SERPINE1 in complex with the somatomedin B
domain of vitronectin [54] shows that the cofactor-binding
site on SERPINE1 is located in a similar region to the
heparin-binding site of SERPINC1 (on and around helices hD
and hE; Figure 3c). Whereas heparin promotes conforma-
tional change in SERPINC1, however, vitronectin prevents
conformational change in SERPINE1. Several other serpins,
including SERPINC1, have been shown to spontaneously
undergo the transition to the latent state, and it is suggested
that this may be an important control mechanism [55]. 
Although the transition to latency could be an important
control mechanism in at least one serpin, an alternative spon-
taneous conformational change, serpin polymerization, results
in deficiency and disease (or serpinopathy) [14,56]. Serpin
polymerization is postulated to occur via a domain-swapping
event whereby the RCL of one molecule docks into -sheet A
of another to form an inactive long-chain serpin polymer
(Figure 4a,b) [14,57-59]. Several important human serpin
variants result in polymerization, the best studied and most
common of which is the Z allele (Glu342Lys) of SERPINA1
[14]. Here, failure to properly control the activity of neutrophil
elastase (the inhibitory target of SERPINA1) in the lung
during the inflammatory response results in the destruction of
lung tissue, leading to emphysema. Furthermore, in individu-
als homozygous for the Z-variant, the accumulation of serpin
aggregates or polymers in the endoplasmic reticulum of anti-
trypsin-producing cells, the hepatocytes, can eventually result
in cell death and liver cirrhosis [14]. Similarly, mutation of
SERPINI1 results in the formation of neural inclusion bodies
and in the disease ‘familial encephalopathy with neuroserpin
inclusion bodies’ (FENIB) [17,60,61]. 
In addition to promoting polymerization, several serpin
mutations have been identified that promote formation of
a disease-linked latent state. Notably, a mutation in
SERPINC1, the wibble variant (Thr85Met), results in forma-
tion of large amounts of circulating latent SERPINC1 (about
10% of total SERPINC1) [55]. An alternative ‘half-way house’
conformation of SERPINA3, termed , has also been identi-
fied (Figure 4c) [62]. The structure of -SERPINA3 also
highlights the extraordinary flexibility of the serpin scaf-
fold: in this conformation the RCL is partially inserted into
-sheet A and helix hF has partially unwound and inserted
into the base of -sheet A, completing the -sheet hydrogen
bonding (Figure 4c). Finally, the promiscuity of -sheet A is
highlighted by the ability of this region to readily accept
short peptides: several structural and biochemical studies
have demonstrated that peptides can bind to -sheet A and
induce the S-to-R transition (Figure 4d).
Valuable insights into the mechanism of serpin function
have been gleaned from the structural location of variants
that promote serpin instability [18,63]. The majority of
serpinopathy-linked mutations (including antitrypsin
Siiyama [64] and Mmalton [65], antithrombin wibble [55]
and -SERPINA3 [62]) cluster in the center of the serpin
molecule, underneath -sheet A, in a region termed the
shutter (marked on Figure 1a). Interestingly, Glu342, the
position mutated in the Z allele of SERPINA1, is located at
the breach, which is just above the shutter at the top of -
sheet A. This portion of the molecule is the point of initial
RCL insertion. It is suggested that destabilization of -sheet
A in either the shutter or the breach is sufficient to favor the
transition to a polymeric or latent state over maintenance of
the monomeric metastable native state [14]. Interestingly,
analysis of conserved residues in the serpin superfamily also
reveals a striking distribution of highly conserved residues
stretching down the center of -sheet A from the breach to
the base of the molecule [1]. 
216.6 Genome Biology 2006, Volume 7, Issue 5, Article 216 Law et al. http://genomebiology.com/2006/7/5/216
Genome Biology 2006, 7:216Unsurprisingly, given the important proteolytic processes
they control, simple deficiencies such as those caused by
null mutations of a large number of human serpins are
linked to disease (some of these are summarized in Table 1).
Interestingly, however, several (rare) mutations have been
identified that do not promote instability but instead inter-
fere with the ability of the serpin to interact correctly with
proteases. These include the Enschede variant of SERPINF2
[66], in which insertion of an additional alanine in the RCL
results in predominantly substrate-like (rather than
inhibitory) behavior upon interaction with a protease. Muta-
tions that alter serpin specificity can also have a devastating
effect. For example, the Pittsburgh variant of SERPINA1
(antitrypsin) is an effective thrombin inhibitor as a result of
mutation of the P1 methionine to an arginine [67]. The
carrier of this variant died of a fatal bleeding disorder in
childhood. 
Our knowledge of the functional biochemistry and cell
biology of serpins has been shaped by extensive contribu-
tions from structural biology and genomics. The structure of
six different serpin conformations, together with analysis of
numerous different dysfunctional serpin variants, has
allowed the characterization of a unique conformational
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
http://genomebiology.com/2006/7/5/216                                                             Genome Biology 2006, Volume 7, Issue 5, Article 216 Law et al. 216.7
Genome Biology 2006, 7:216
Figure 3
Spontaneous conformational change in serpins. (a) Structure of native SERPINE1 (PDB code 1B3K) [96]. The RCL is in magenta and strand s1c of -
sheet C is in yellow. (b) The structure of latent SERPINE1 (PDB code 1DVN) [53,97], which can form by spontaneous conversion from the native
protein. The RCL (magenta) is inserted into -sheet A. In order to enable full insertion of the RCL, s1C of -sheet C (pale yellow) has peeled off. In
addition, conformational change in the strands s3C and s4C (pale green) is indicated. (c) Structure of SERPINE1 (blue) in complex with the somatomedin
B domain (green) of vitronectin (PDB code 1OC0) [54]. The interaction with vitronectin locks SERPINE1 in the native, active conformation.
s1C
RCL
s4C
Formerly s1C
Somatomedin B domain
of vitronectin
+
Spontaneous
conformational
change
Native SERPINE1
Latent SERPINE1
SERPINE1 -
vitronectin complex 
(a) (b)
(c)
s3Cmechanism of protease inhibition. These data highlight the
intrinsic advantages as well as the dangers of structural com-
plexity in protease inhibitors. On the one hand, conforma-
tional mobility provides an inherently controllable
mechanism of inhibition. On the other, uncontrolled serpin
conformational change may result in misfolding and the
development of specific serpinopathies. Serpins thus join a
growing number of structurally distinct molecules that can
misfold and cause important degenerative diseases, such as
prions, polyglutamine regions of various proteins and the
amyloid proteins that form inclusions in Alzheimer’s
disease. While the mechanism of serpin function is now
structurally well characterized, the precise role and biologi-
cal target of many serpins remains to be understood.
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